Alpha Tau Medical LtdDRTS
Price$14.91

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$42.6MTTM through 31 Dec 2025
Free Cash Flow -$32.8MTTM through 31 Dec 2025

Margins

Current

Returns

-55.3%ROE
-40.3%ROA

Balance Sheet Health

Debt / Equity0.08x
Current Ratio7.45x
Net Debt-$66.8Mnet cash position
Cash & Equivalents$12.2M

Quality Metrics

Altman Z-Score26.35
Piotroski F-Score1 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Diluted EPS-$0.53TTM
'19'20'21'22'23'24'25
FY2025: $-0.53

Dividend

No dividend

Capital Allocation

R&D Spend$32.1M

Segment Performance

SegmentRevenueYoYOutlook
Alpha DaRT Development$0
View details

Focusing on completing patient recruitment in the ReSTART pivotal U.S. trial and preparing for commercialization.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.